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Background
The global health community pays
renewed attention to evaluating the feasi-
bility of elimination and eradication of
certain communicable diseases [1,2] be-
sides continuing to reduce the burden of
ill-health. Eradication depends on both the
availability of tools to interrupt transmis-
sion, the capacity of health systems to
implement these solutions effectively
across all populations concerned, the
required resources, and sustained political
will. While the health and economic
benefits of disease elimination and subse-
quent eradication may be substantial,
elimination initiatives represent resource-
intensive efforts with associated opportu-
nity costs [3,4]. Given the increasingly
intense competition for global health
resources, the decision to commit to
national/regional elimination or eventual
global eradication initiatives needs to be
based upon robust analysis of benefits,
risks, and costs.
Following an initial proposal of the
Ernst Stru¨ngmann Forum, convened in
2010 to explore the prospects, feasibility,
and challenges of disease eradication [2], a
working group developed a Guide to
Preparing an Eradication Investment Case
(EIC) [5]. The Guide proposes a generic
approach applicable to any potentially
eradicable disease.
Among the diseases tentatively identi-
fied as amenable to eradication are several
neglected tropical diseases (NTDs) [6].
The vision of eliminating and eradicating
selected NTDs has gathered momentum
over recent years. In 2011, the WHO
Strategic and Technical Advisory Group
for Neglected Tropical Diseases and its
partners adopted a roadmap for the
control, elimination, and eradication of
many NTDs. The global financial support
for NTDs control and elimination is still
comparatively low but has recently started
to substantially increase. Following major
pledges by the US Agency for Interna-
tional Development (USAID) (350 million
USD for the period 2009–2013) and the
UK’s Department for International De-
velopment (DfID) for 2011–2015 (245
million GBP), the Bill and Melinda
Gates Foundation (BMFG) donated
363 million USD for NTDs control
and elimination in January 2012 (Lon-
don Declaration, http://endtheneglect.
org/2012/01/ntds-take-spotlight-at-london-
declaration-meeting/).
Eradication Investment Cases:
An Innovative Method to Assess
Global Health Investments
The essence of economics, namely to
study how societies make resource alloca-
tion decisions, is answering three funda-
mental questions: 1) What products and
services to produce? 2) How to produce
them—adopting which production pro-
cesses? 3) For Whom to produce products
and services (who should benefit from the
production and use of these products and
services)? The first and second questions
are related to the concept of efficiency—
allocative and technical—while the third
also addresses equity and fairness issues.
The overall objective is usually maximiz-
ing social benefits, taking into account
distributional effects or equity, with differ-
ent societies placing different weights to
efficiency and equity objectives.
An EIC is essentially an economic
composite assessment in the broader
meaning of economics, addressing thus
all three fundamental economics ques-
tions. An EIC in fact answers: 1) the
‘‘What’’ question, that compares remain-
ing in control mode versus moving toward
elimination and then eradication; 2) the
‘‘How’’ question,’’ assessing which inter-
vention/s or strategy/ies should be adopt-
ed by which stakeholder, how much
resources would be required, and how
they could be mobilized (priority setting
and resources allocation, funding); and 3)
the ‘‘for Whom’’ question, assessing who
would benefit from control or elimination
in terms of health and economic gains,
and the likely impact on equity and
fairness.
An EIC is an approach to assess global
health investments that, following the
Guide [5] mentioned above, is structured
into three main components:
(1) A description of the proposed
investment, providing a summary of
the specific problem that the EIC is
addressing and describing scenarios
which, if properly implemented, could
lead to elimination and ultimately
eradication of the disease.
(2) The rationale for investing, doc-
umenting the evidence on the biolog-
ical, technical, social, and political
feasibility, the estimates of the costs
of potential approaches and their
health and economic impact, the
demand for elimination/eradication,
and willingness to cooperate at the
global, national, and local levels.
(3) The management and gover-
nance aspects of the elimination/
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eradication initiative, describing the
managing agency, the organizational
arrangements, the role of all relevant
partners involved in the elimination/
eradication initiative at all levels—
global, national, and local—including
their responsibilities—e.g., technical
support, monitoring and evaluation,
etc.—and an assessment of their
capacity.
This article presents the rationale, the
approaches to be pursued, and the main
methodological challenges of developing
EICs for three neglected tropical diseases
considered as candidates for elimination
and eradication [4]: onchocerciasis (river
blindness), lymphatic filariasis (LF) (ele-
phantiasis), and human African trypano-
somiasis (HAT) (sleeping sickness). Clearly,
an EIC is a broad and innovative
methodology to assess the potential con-
sequences of investing in elimination and
eradication of a disease. It is aimed at
going beyond the traditional reductionist
approaches focusing on only one or few
dimensions—e.g., the health impact or the
cost-effectiveness—that are relevant for
informing policy decisions. Nevertheless,
developing EICs, following the approach
proposed by the Guide [5] mentioned
above, presents several challenges.
Challenges to Developing EICs
for Onchocerciasis, LF, and HAT
There are several methodological chal-
lenges to developing EICs in general, and
for onchocerciasis, LF, and HAT in
particular. These challenges can be
grouped into nine broad categories that
are outlined below.
Developing Realistic Scenarios to
Move from Control to Elimination
and Eradication
Developing EICs requires that scenarios
be defined which can then be compared.
A scenario is a full description of all
activities required to achieve the intended
outcome (i.e., control, elimination, or
eradication) of the target disease if com-
prehensively and diligently implemented
for as long as might be required to reach
the desired outcome, sometimes decades
later. Scenarios outline different options to
move from control to elimination using
different mixes of integrated interventions
tailored to a given endemic setting.
In the EICs, the counterfactual scenario
is always the current strategy to combat a
given disease, implemented at the current
intensity and coverage. Three broad
scenarios are then comparatively assessed:
a) Maintaining the current control (or
elimination) efforts;
b) Improving effectiveness and scaling
up current control (or elimination)
strategies to faster achieve elimina-
tion in given settings by using differ-
ent strategies/intervention mixes;
c) Progressive extension of the disease-
free area until eradication is achieved
using proven effective intervention
mixes but tailored to the setting.
The scenario characterization includes
a list of country-specific parameters de-
scribing the epidemiological situation and
past efforts to combat the disease, opera-
tional thresholds defining the transition
between program stages (e.g., from control
to elimination mode, from periodic treat-
ment to surveillance and response mode,
etc.), pre- and post-elimination activities
such as surveys to determine the epidemi-
ological situation throughout the elimina-
tion phase and to attain and sustain
elimination, and the anticipated need for
routine health system–based disease sur-
veillance to rapidly detect—and respond
to—an eventual reemergence of the dis-
ease.
The scenarios for moving from control
to elimination and eradication of oncho-
cerciasis, LF, and HAT are built on a
comprehensive and systematic historical
review of the evidence on the local
epidemiology, achieved population and
regional coverage of interventions to
control the diseases, and the achievements
of the major global initiatives set up to
control them. The review collects and
analyzes data available from the WHO
NTDs programs and from any possible
disease-specific global initiatives. It in-
cludes data by country and region,
mapping the areas of overlap of oncho-
cerciasis, LF, and HAT, as well as other
NTDs and additional major infectious
diseases, and assessing the implications of
ongoing control strategies and their esca-
lation to elimination and eradication
strategies.
The feasibility analysis of eradicating
onchocerciasis, LF, and HAT considers
the biological, epidemiological, social,
economic, and political aspects in line
with the criteria defined by the Interna-
tional Task Force on Disease Eradication
and the consensus found by the Ernst
Stru¨ngmann Forum [7]. The biological
and epidemiological criteria include epi-
demiological vulnerability, availability of
effective practical interventions likely to
achieve eradication, and demonstrated
feasibility. The social and political criteria
include a broad appreciation of the social
importance of the disease, reasonable
projected costs, synergies with other health
system activities, and the contextual and
political urgency for elimination/eradica-
tion rather than control.
The definition of scenarios and the
analysis of the feasibility of elimination
and eradication require simplifications of
real-life conditions—i.e., a strong and
coherent focus on the minimal essential
information of the epidemiological, oper-
ational (implementation), and contextual
conditions. The scenarios depend largely
on existing data that often are not of the
desired quality and not available for all
settings. Predictions over years or even
decades must then be made based on the
available data, magnifying any imperfec-
tion in baseline data and requiring robust
sensitivity analysis. This pragmatic ap-
proach leads to the best possible equilib-
rium between precision and feasibility.
Moreover, the scenarios compared are
developed in consultation with all inter-
ested stakeholders to reach consensus and
wide acceptance among the global public
health community and its major stake-
holders which in turn renders an EIC
widely credible.
Global Analyses of Long-Term
Impacts
The EICs are global analyses that in
principle would require data from all
endemic countries. However, these data
are often only partially available and/or
not of the quality needed. Consequently,
respective adjustments and generalizations
have to be made. Similarly, operational
thresholds defining the transition between
program activities need to be defined, but
it must be considered that they do not
always correspond to local epidemiological
thresholds, e.g., transmission breakpoints
may vary while the thresholds allowing
cessation of periodic treatment and com-
mencement of surveillance need to be
standardized for operational reasons. Dis-
ease control approaches ideally protect
individuals and reduce public health
burden. They may as well have some
partial effects on transmission. Elimination
and eradication instead have an immedi-
ate impact on the transmission and thus
also lower the burden, but moreover also
protect future generations from the risk of
infection, making future control measures
unnecessary. The impact of disease control
can therefore be measured in a shorter
time frame, while the impact of elimina-
tion and eradication should be primarily
evaluated based on its long-term effects.
Consequently, EICs require long-term
predictions and imply decisions on how
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much value to give to future generations’
health benefits and costs. While acknowl-
edging the rather controversial aspect of
whether or not to discount future health
benefits and costs, and if yes, whether to
discount benefits less than costs, the long-
term dimension also—and equally impor-
tantly—requires assessing long-term polit-
ical feasibility of the initiatives which
includes the long-term reactions of all
stakeholders involved. Therefore and at a
practical level, EICs must adopt robust
methods and approaches to assess the
impact of uncertainty in models and
parameters used.
Disease Elimination and Eradication
Are Global Public Goods
Disease elimination and eradication are
global public goods. It is not, in fact,
possible to exclude a country or a
community from the benefits of eradica-
tion efforts, and every country/community
can benefit from eradication efforts with-
out limiting the others’ benefits. As a
consequence, each country’s decision to
eliminate a disease is likely to depend on
whether other countries also are eliminat-
ing/have eliminated the disease. In order
to achieve eradication, all countries need
to engage in elimination. If only one
country does not do it, then eradication
cannot be achieved. Thus, coordination
and incentives to coordinate are of para-
mount importance. Interdependence of
decisions to eliminate mainly depends
upon geographical circumstances. Clearly,
for countries that share borders the success
of elimination depends also on the decision
of the neighbors to eliminate. As the
majority of NTD-endemic countries are
neighbors, the decisions to control or
eliminate are often deeply interrelated. In
EICs therefore, coordination and incen-
tives to coordinate are important factors to
be taken into account as only with an
effective cooperation at global, national,
and local levels is it possible to move from
control to elimination. Hence, the EICs
will assess for each disease how critical
cooperation is for success at the various
levels, particularly with regard to sharing
information about surveillance, diagnos-
tics, forecasting of demand of commodities
for elimination, and coordinating purchas-
es. The analysis will focus specifically on:
(i) the potential role of all various interna-
tional agencies in the global effort to
eliminate and then eradicate onchocerci-
asis, LF, and HAT; (ii) the nature and
extent of the required commitment of
government agencies; (iii) the political
support required at local levels; and (iv)
the available mechanisms for structuring
robust, durable agreements.
Assessing Long-Term Health
Impacts
The long-term health impact of the
scenarios can be assessed using epidemio-
logical models that include estimates for
transmission interruption thresholds and
consider the risk of reemergence of the
disease as well as the potential implications
of rising life expectancies over time. A
recent review article showed that more
research is needed to develop methods to
link dynamical models of infection and
disease, parameterize models to allow
greater location specificity, and better
understand long-term effects of drug
efficacy on parasite populations and mor-
bidity, allowing in turn robust health
impact assessments and cost-effectiveness
analyses [8].
For onchocerciasis, the assessments and
predictions developed so far involved
stochastic microsimulations to calculate
the life events of individual persons and
colonizing parasites, or deterministic vec-
tor models of the dynamics of the Simulium
populations and the development of the
parasite in the black flies [9–11]. Based on
field observations and the results of the
carefully parameterized model ONCHO-
SIM, elimination of onchocerciasis from
most endemic foci in Africa appears to be
possible. However, the same model sug-
gests that the requirements for global
eradication in terms of intervention dura-
tion, coverage, and frequency of treatment
may be prohibitive given the current tools
and under current funding levels, partic-
ularly in highly endemic areas [12].
Similar modeling approaches have been
applied to LF [13–15]. Particular consid-
eration needs to be given to the existence
of the three different LF species (Wuchereria
bancrofti, Brugia malayi, and B. timori),
endemic in different places and transmit-
ted by different vectors. There have been
several modeling exercises addressing the
dynamics of LF transmission in specific
localities [16].
A deterministic model of HAT suggests
that the vector numbers generally need to
be reduced by 90% to achieve local
elimination [17]. An agent-based model
has been used in order to incorporate the
spatial dimension of transmission [18], but
ecological differences between endemic
foci obviously affect the feasibility of tsetse
control. These have received little consid-
eration in dynamic models of HAT. There
also remain important uncertainties about
disease progression which may have sub-
stantial implications [19,20]. There are
also important differences between T.b.
gambiense and T.b. rhodesiense in terms of the
significance of the animal reservoir, hu-
man infectiousness, and pathology [20–
22], all of which need to be taken into
consideration.
Finally, the health impact of the differ-
ent scenarios can be measured in terms of
number of cases, deaths, and burden
averted (expressed in DALYs) which in
turn allow comparisons with the impact of
interventions to control other diseases
[23].
Assessment of Financial and
Economic Costs
Another set of challenges are related to
estimating the financial and economic
costs of the interventions to eliminate
and eradicate a disease. The total financial
and economic costs of the various scenar-
ios include capital and recurrent costs for
all core categories. Further disaggregation
by country income group (e.g., using
World Bank income groups based on gross
national income [GNI] per capita) may be
used to illustrate asymmetries in costs (and
benefits) as a function of country income.
The costs will be presented stratified into
those to achieve elimination and those to
sustain elimination with the goal of
eradication. Nevertheless, limited data
are available on both financial and
economic costs of interventions to control
and eliminate onchocerciasis, LF, and
HAT, and available data often do not
distinguish between resource use and unit
costs. Consequently, respective approxi-
mations with best and worst case estimates
are made.
A further challenge is the limited
evidence on how to take into account the
potential for diminishing returns to scale
and an increase in unit costs as programs
are expanded to cover groups that are
harder and harder to reach. Specific
costing models should therefore be devel-
oped for estimating the costs of activities
such as periodic surveys and surveillance,
and to account for the needed initial
investments.
The impact on labor productivity of
these diseases is equally important and
presents further challenges due to difficul-
ties in both measuring and valuing this
specific impact. For instance, troublesome
itching and vision impairment due to
onchocerciasis are associated with de-
creased productivity at individual level
and a loss of labor and a degraded
productivity at societal level. However,
measuring the microeconomic impacts of
ill health and generalizing them is prone to
difficulties and controversies about the
PLOS Neglected Tropical Diseases | www.plosntds.org 3 November 2013 | Volume 7 | Issue 11 | e2446
approaches to be adopted [24], particu-
larly in the case of onchocerciasis, LF, and
HAT that affect largely highly marginal-
ized populations.
Assessing Cost-Effectiveness and
Broader Economic Impacts
Cost-effectiveness analyses yield esti-
mates of the monetary costs of alternative
means of producing an effect or outcome
that needs not be measured in monetary
terms [20,25–27], for example the cost of
immunizing a child or the cost per healthy
year of life gained. In the EICs, the cost-
effectiveness analysis takes a societal per-
spective, capturing the costs and benefits
before and after achieving elimination.
The framework for the benefit-costs as-
sessment thus extends the net-benefit
framework to include an additional term,
the net benefits of interrupting transmis-
sion to achieve elimination.
Both costs and effects occurring in the
future are discounted using different
discount rates and the implications of
chosen discount rates on the results are
assessed. It has been suggested that
constant discounting may undervalue the
future [5]. Given the relevance of dis-
counting in the EICs, the impact of
applying a discount rate for health effects
that is lower than that of costs, but above
zero, should be tested. In addition, the
results should be presented after applying
a nonconstant discount rate (declining or
‘‘slow’’ as opposed to exponential dis-
counting; i.e., discounting at a constant
rate) [5], allowing decision makers to
appreciate the impact of these methodo-
logical choices on the results.
The sensitivity of the economic analysis
to possible variations in the values of
critical parameters should also be exam-
ined. The parameters chosen for the
sensitivity analysis relate to identified
project constraints or critical risks and
prediction errors (such as prices or dis-
count rates). Probabilistic sensitivity anal-
ysis is run to account for parameter
uncertainty.
Cost-benefit analysis requires monetary
estimates of both costs and effects. Cost-
benefit analysis is useful, for example
where it is necessary to make intersectorial
or cross-project comparisons such as a
comparison between a health and educa-
tion project. Nevertheless, how to extend
cost-effectiveness analysis to cost-benefit
analysis of health interventions is contro-
versial. In particular, the use of the value
of a statistical life to monetize benefits has
been rejected by WHO and is therefore
not adopted in our EICs. Instead, the
EICs assess wider economic benefits of
elimination/eradication. These include an
assessment of the impact of interventions
on economic productivity and develop-
ment. The economic analysis explores the
pathway(s) through which elimination or
eradication can affect economic activity
both at the individual household and
population level, including the different
mechanisms through which health can
affect income (e.g., productivity, children’s
education, savings and investments, and
demographic structure) [24].
The assessment of broader economic
impacts of eliminating onchocerciasis, LF,
and HAT presents further challenges.
First, the impact at country level may
not be very high because of the low and
often very focal incidence and prevalence
of these diseases. In addition, the available
data and the methods for assessing the
impacts on economic development are
limited. For example, it is by definition not
possible to carry out pre-post studies using
quasi-experimental designs. Nevertheless,
elimination of onchocerciasis, LF, and
HAT are indeed expected to have an
impact on economic growth and develop-
ment through the effects, for instance, on
the agricultural sector and on human
capital accumulation. However, it is not
only hard to find good indicators that
capture these impacts, but also current
control efforts have already brought sub-
stantial economic benefits and so further
benefits of elimination/eradication might
be smaller than expected.
Assessing Broader Social Impacts
The eradication of onchocerciasis, LF,
and HAT might have positive and nega-
tive social impacts. The social impact
includes intergenerational benefits and
the contribution of elimination/eradica-
tion of these diseases to attain public goods
such as reducing global health inequity.
Positive social impacts may include the
elimination of stigma; economic and
quality of life improvements; increases in
mobility and productivity, in education
attainments, and in access to care; and
structural improvement of health care
services, community participation, and
democracy. A negative impact may result
from how the project is implemented, e.g.,
from coercion, fear, an excessive pressure/
workload of health personnel, and the
diversion of funds from more beneficial
areas of intervention.
A recent systematic review conducted
by the Swiss TPH documented social
impacts of onchocerciasis, LF, and HAT
[28]. It analyzed the evidence on: a) the
psychosocial and social impacts of the
diseases; b) the social determinants of these
diseases at community level, including
social inequalities; c) people’s knowledge,
practices, and health-seeking behavior
related to the three diseases; and d) social
aspects related to the programs, particu-
larly the social and micropolitical contexts
of community-directed drug distribution
(in onchocerciasis and LFs programs) and
its influence on the development and
functioning of the program, and the social
factors that enable or hinder coverage and
adherence to medication. The review
revealed that these impacts, although
important, are however hard to measure
and even harder to quantify.
Modeling Interactions between
Disease Control Programs
Another set of challenges for developing
these EICs for onchocerciasis, LF, and
HAT are related to the fact that the
elimination and eradication initiatives will
be happening in a context of, sometimes
rapid, scale up of different interventions to
control or eliminate other NTDs as well as
other infectious diseases such as malaria.
In many areas, onchocerciasis and LF are
co-endemic, and scaling up coverage of
interventions to prevent or treat one of
them will result in substantial impact on
the other as the same drug, i.e., ivermec-
tin, is used for the treatment of both. This
is also true for other diseases such as
malaria where the ongoing initiatives to
scale up vector control may have substan-
tial impacts on LF [29]. Thus, the
integration of control and elimination
initiatives must be taken into account
and the impact evaluated not only on the
epidemiology of the diseases but also from
a programmatic point of view, e.g.,
considering local capacity and health
systems. In addition, economic conse-
quences of program integration must be
carefully evaluated.
Assessment of Short- and Long-
Term Health Systems’ Needs and
Impacts
Health systems play a crucial role in
achieving control, elimination, and then
eradication of onchocerciasis, LF, and
HAT, and hence their capacity in large
part determines the feasibility of reaching
these goals. The historical experience of
onchocerciasis control shows how difficult
it is to sustain high treatment coverage
with ivermectin, even when the drug is
donated. Communities play a decisive role
in the community-directed treatment
(CDTi) strategy, implying that health
systems must empower local communities
as well as health services. CDTi is seen as
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an effective approach to strengthening
peripheral and district health systems [30].
Interestingly, important differences exist
between regions with regard to the most
suitable avenues for mass drug adminis-
tration. Similarly to onchocerciasis, LF
control relies on the periodic administra-
tion of ivermectin (or Diethylcarbamazin
(DEC)-mediated salt outside Africa) to-
gether with albendazole to a large fraction
of the population residing in endemic
areas. While CDTi appears to work
reasonably well in many African settings,
efforts to replicate this model in other
regions mostly failed. Instead, in Asia, the
Pacific, and the Western hemisphere
distribution through the health care sys-
tem is arguably more successful.
HAT is one of the few diseases where
effective control depends on active
screening to ensure the early detection
of cases. Symptoms in the initial phase of
the illness, when treatment has the
greatest chance of success, are often mild
or nonspecific. The capability of the
health system to detect cases and respond
quickly is thus very important. Eliminat-
ing HAT requires massive efforts in
targeted active case detection and a
substantial strengthening of passive case
detection; the latter strengthens health
systems so that misdiagnosis and under-
reporting are reduced. Finally, there
must be a coordinated multisectoral
approach to tsetse control that involves
specialists in human and animal health,
livestock, agriculture, tourism, wildlife,
and vector control.
The concept of health systems effective-
ness can be adopted to analyze health
systems constraints to elimination [31].
The major health system factors can be
grouped into those related to the avail-
ability of competent human resources;
managerial capacity in general health
services to plan, implement, and monitor
interventions; procurement and supply
chain management; delivery systems; dis-
ease surveillance and response; national
and local information systems; involve-
ment of communities in intervention
delivery; and financing.
Integration of the elimination initiatives
into national and local health systems, and
Building Scenarios for Eliminating and Eradicating Onchocerciasis, Lymphatic Filariasis, and Human
African Trypanosomiasis
Onchocerciasis Onchocerciasis control relies on the control of the Simulium spp. vectors and the administration of ivermectin
to at least 65% of the at-risk population for many years [34]. Recent evidence indicates that mass treatment with ivermectin is
not only a strategy for controlling onchocerciasis as a public health problem, but that it can also interrupt transmission and
eliminate the parasite in endemic foci if high treatment coverage can be maintained for a decade or more, depending on the
local epidemiological situation [35]. For the purpose of the EIC, the scenario to move toward elimination of onchocerciasis is
based on the current strategy of community-directed treatment with ivermectin (CDTi), with coverage extended to all areas
where there is local transmission, i.e., a nodule prevalence .5% (traditionally, interventions focus on areas with a nodule
prevalence .20%), and sustained mass treatment up to demonstrated elimination in the entire focus. Thereafter, periodic
epidemiological and entomological surveys as well as passive surveillance need to be maintained pending global elimination
(i.e., eradication). Maintaining mass treatment for the required duration is a major challenge in regions with weak governance
and health system capacity.
Lymphatic filariasis (LF) With regard to LF, spectacular results have been achieved in many settings where traditionally high
prevalence and disease burden have been reduced through concerted efforts in vector control and mass drug administration,
relying on ivermectin in Africa and DEC in other regions, both now usually co-administered with albendazole [36]. LF control
targets all areas where local transmission of LF has been detected (e.g., though surveys). While LF control is well advanced in
many countries in Asia, the Pacific, and in the Western hemisphere, implementation is much slower in Africa where a range of
countries still need to update epidemiological maps and establish national programs targeting the entire at-risk population
[37]. In order to be successful, elimination programs need to achieve coverage of the at-risk population in excess of 65%, and
maintain it for several years, depending on the local epidemiological situation, vector fauna, and other factors (often around six
years) [38]. Thereafter, regular surveys and surveillance are required in order to detect recrudescence.
The EIC scenarios take into account that in areas where onchocerciasis and LF are co-endemic (mainly in Africa), close
collaboration is required between the two elimination programs as both programs rely on ivermectin distribution by
community volunteers, require post-treatment surveillance, and drug distribution for either program cannot come to
conclusion—and thus surveillance cannot be started—if the other program is continuing ivermectin treatment in the same
area. Considering the generally much longer time horizon of onchocerciasis control programs compared to LF control
programs, the duration of the former will be the decisive factor in most areas. On the other hand, it must be noted that LF has
been found to reemerge after near-elimination in certain areas [39]. Last, LF elimination is furthered in areas where it is
transmitted by Anopheles spp. mosquitoes by efforts to control malaria with long-lasting insecticidal-treated bednets (LLITNs).
Other forms of vector control might also play a role even if not designed and implemented for LF control [40].
Human African Trypanosomiasis (HAT) The scenarios for HAT control focus on eliminating the parasites causing human
disease rather than the vector (tsetse flies). Hence, case detection (active and passive) and treatment are the mainstay of the
scenarios, with these efforts supported by targeted interventions to reduce vector density with a view of reducing transmission
(e.g., using insecticide-treated targets and cattle) [41]. Scenarios also take into account that while in T.b. gambiense–endemic
areas eradication is conceptually feasible (none or very limited animal reservoir), in T.b. rhodesiense–endemic areas the mere
concept of eradication is questionable as Glossina spp. (vector) elimination would need to be achieved due to the presence of
extensive animal reservoirs, including in wild animals [42]. Thus, the scenarios for T.b. gambiense will aim at ‘‘eradication’’ while
those for T.b. rhodesiense will aim at ‘‘elimination in humans.’’ As a consequence of focusing on the parasite causing human
disease and neither trypanosomes in general nor the tsetse flies transmitting them, the economic benefits of elimination and
eradication will chiefly result from improved public health and reduced suffering rather than increases in livestock production
and improved agricultural opportunities.
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thus into regular health planning, may be
needed to scale up the interventions and
sustain high coverage for long periods.
There is also scope for integration of
onchocerciasis and LF programs as both
rely on similar delivery strategies and
interventions and could therefore be
managed and planned together.
Disease surveillance is increasingly im-
portant when the disease burden is
lowered in the pre-elimination and elim-
ination phases. Disease surveillance cou-
pled with active response strategies can be
seen as an intervention that needs to be
effective and dynamic, and therefore
integrated into functional health systems.
The health system impact assessment
can be conducted following systems think-
ing principles [32]. Systems thinking helps
to reveal the underlying characteristics
and relationships of the key functions of
the overall system. It is applied to
anticipate how the control/elimination/
eradication strategy might have system-
wide effects across the systems building
blocks—leadership and governance,
health system financing, health work-
force, health information systems, medical
products, vaccines and technologies, and
service delivery. It tries to identify syner-
gies to strengthen the system and avoid
detrimental unintended consequences that
can be mitigated [33].
Conclusion
The EIC framework provides a meth-
odology by which the feasibility, costs, and
consequences of elimination and eradica-
tion of candidate diseases can be assessed.
The EICs aim to go beyond traditional
efficacy and efficiency measures to take
into account multiple dimensions of such
endeavors, including their implications for
health systems and wider economic bene-
fits. Although promising, the EICs ap-
proach proposed by the recent Guide [5]
has not yet been applied to any disease
program. In this article, we described the
approach and main challenges or bound-
ary conditions to develop EICs for oncho-
cerciasis, LF, and HAT. We show how the
EIC approach goes beyond traditional
efficacy and efficiency measures to take
into account multiple dimensions. The
results of the EICs for onchocerciasis, LF,
and HAT will serve not only to inform
decisions of global and national policy
makers but also to test the applicability of
the EICs framework at the national and
global level.
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